Haemonetics Corporation

HAE Healthcare Medical Devices

Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025. In the quarter to June 2026, revenue grew 5.60%, EPS grew 2.86%, free cash flow grew 220.4% and total debt rose 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

118.28 3.01 −2.48%
Market cap
$5.5B
P/E
57.7×
Fwd P/E
18.0×
Dividend yield
—
F-score
6/9
Altman Z
2.21
Beneish M
−2.81
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

14.17 21.96 27.76 36.59
P/S ratio
1.75 2.84 1.99 2.52
P/FCF ratio
8.95 12.04 10.16 11.63
P/Operating CF
20.84 40.08 37.48 65.02
P/B ratio
2.73 4.11 3.34 4.06
Price to Tangible BV
0.00 0.00 0.00 0.00
EV/Sales
2.22 3.27 2.72 3.22
EV/EBITDA
8.01 11.57 13.25 15.88
EV/Operating CF
10.18 12.71 12.39 13.25
EV/FCF
11.36 13.83 13.88 14.86
Quick Ratio
0.92 1.04 1.64 1.67
Current Ratio
1.64 1.75 2.95 3.08
Net Debt/EBITDA
7.03 5.79 226.86 11.18
Debt/Assets
37.69% 36.93% 50.90% 49.43%
Debt/Equity
1.08 1.01 1.53 1.40
Asset Turnover
0.53 0.53 0.55 0.56
Operating CF/Net income
2.88 2.09 (3.52) 1.59
Capex/Depreciation
(0.16) (0.21) (0.63) (0.28)
Interest Coverage
8.12 9.08 (4.28) 5.81
Research and Development Expense of Revenue
4.54% 4.19% 4.17% 4.77%
Selling, General and Administrative Expense of Revenue
31.05% 32.20% 34.92% 35.05%
Intangible Assets out of Total Assets
0.42 0.41 0.46 0.46
Share Based Compensation of Revenue
2.32% 2.30% 2.64% 2.74%
Graham Net Nets
(0.30) (0.17) (0.29) (0.21)
Graham Number
37.16 40.00 27.77 29.18
Earnings Yield
7.06% 4.55% 3.60% 2.73%
Free Cash Flow Yield
11.17% 8.30% 9.85% 8.60%
Revenue per Share
6.88 7.24 7.34 7.48
Operating CF per Share
2.34 2.00 1.50 1.15
Capex per Share
(0.10) (0.13) (0.36) (0.17)
Free Cash Flow per Share
2.24 1.87 1.14 0.98
Cash per Share
6.23 7.77 5.20 4.92
Shareholders Equity per Share
17.84 19.48 16.88 18.45
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
17.84 19.48 16.88 18.45
Free Cash Flow
106.43 87.65 53.81 44.65
Working Capital
351.36 403.81 552.28 547.60
Capital Expenditures
(4.90) (5.92) (17.13) (7.67)
Net Current Asset Value
(693.30) (635.76) (764.73) (717.47)
EV/EBIT
12.13 17.15 23.18 27.12
Capex to Sales
0.02 0.02 0.05 0.02
Price to Operating Income
9.56 14.94 16.97 21.22
Other line items
Average Receivables
210.30 203.83 209.76 208.41
Average Payables
65.47 55.84 59.03 51.17
Average Inventory
359.16 340.40 335.76 333.63
Average Assets
2,483.69 2,511.08 2,423.44 2,413.75
Average Common Equity
864.01 909.16 808.58 859.70

Fold the line items

Columns are period end dates